The therapeutic effect and specific mechanism involved active Chinese medicine component biochaninA in glioma.
Overview
- Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
- Fudan University – Dr. Kong Joint Research Center for Sports Medicine and Health Footwear, Fudan University Institute of Sports Medicine (Jinqiao Laboratory), Shanghai, China
- Department of Neurosurgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
- Acupuncture and Massage College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China
- Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, China International Neuroscience Institute (CHINA-INI), National Medical Center for Neurological Disorders, Beijing, China
- Institute of Literature in Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
Abstract
Introduction: Glioma is a common primary solid brain tumor with high incidence and poor prognosis. Biochanin A (bioA), an active component of traditional Chinese medicine, has potential therapeutic effects on it, but its mechanism remains unclear. This study aimed to clarify its mechanism via a multi-omics strategy.
Methods: A multi-omics integration approach was adopted, which combined single-cell RNA sequencing, in vitro experiments, the construction of a Glutathione S-transferase P1 (GSTP1)-based prognostic model, and analyses of immune infiltration and drug sensitivity to evaluate its clinical value.
Results: C2 CENPF⁺ tumor cells were specifically expressed in recurrent gliomas and associated with the bioA pathway. GSTP1 was the key target gene of bioA; its high expression was related to poor prognosis, and its knockout could inhibit glioma progression. The GSTP1-based prognostic model had excellent predictive efficiency.
Discussion: BioA may exert anti-glioma effects by regulating GSTP1, providing theoretical support for its clinical application and a new therapeutic target for glioma.
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data and to no code of its authors: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- geo:GSE182109, at NCBI GEO; found in the text, “ScRNA-seq data”
Data availability statement
The original contributions presented in the study are included in the article/
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 29 September 2026: the first record
Recorded: type, language, journal, volume, pages, dates, 10 authors, 7 keywords, 11 MeSH terms, 87 references.
Cite
This paper
Chai, D., Xi, M., Gao, L., Sun, L., Kong, D., Zhu, Y., Zhang, J., Cai, Q., Xiao, X., & Wang, C. (2026). The therapeutic effect and specific mechanism involved active Chinese medicine component biochaninA in glioma. Frontiers in immunology, 17, 1780159. https://
BibTeX
@article{chai2026therape
author = {Chai, Dan and Xi, Mengran and Gao, Lu and Sun, Lei and Kong, Desong and Zhu, Yujie and Zhang, Jinghua and Cai, Qiang and Xiao, Xinru and Wang, Changqing},
title = {{The therapeutic effect and specific mechanism involved active Chinese medicine component biochaninA in glioma}},
journal = {Frontiers in immunology},
year = {2026},
month = apr,
volume = {17},
pages = {1780159},
publisher = {Frontiers Media SA},
issn = {1664-3224},
doi = {10.3389/
url = {https://
pmid = {42093975},
pmcid = {PMC13139340}
}
RIS
TY - JOUR
AU - Chai, Dan
AU - Xi, Mengran
AU - Gao, Lu
AU - Sun, Lei
AU - Kong, Desong
AU - Zhu, Yujie
AU - Zhang, Jinghua
AU - Cai, Qiang
AU - Xiao, Xinru
AU - Wang, Changqing
TI - The therapeutic effect and specific mechanism involved active Chinese medicine component biochaninA in glioma
T2 - Frontiers in immunology
J2 - Front Immunol
PY - 2026
DA - 2026/
VL - 17
SP - 1780159
SN - 1664-3224
PB - Frontiers Media SA
DO - 10.3389/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.3389/
"type": "article-journal",
"title": "The therapeutic effect and specific mechanism involved active Chinese medicine component biochaninA in glioma",
"container-title": "Frontiers in immunology",
"author": [
{
"family": "Chai",
"given": "Dan"
},
{
"family": "Xi",
"given": "Mengran"
},
{
"family": "Gao",
"given": "Lu"
},
{
"family": "Sun",
"given": "Lei"
},
{
"family": "Kong",
"given": "Desong"
},
{
"family": "Zhu",
"given": "Yujie"
},
{
"family": "Zhang",
"given": "Jinghua"
},
{
"family": "Cai",
"given": "Qiang"
},
{
"family": "Xiao",
"given": "Xinru"
},
{
"family": "Wang",
"given": "Changqing"
}
],
"container-title-short":
"volume": "17",
"page": "1780159",
"DOI": "10.3389/
"PMID": "42093975",
"PMCID": "PMC13139340",
"ISSN": "1664-3224",
"publisher": "Frontiers Media SA",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
4,
21
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.3389/fimmu.2025.1614549
- Single-cell and spatial atlas of glioblastoma heterogeneity: characterizing the &
lt;i& gt;PCLAF& lt;/ i& gt;+ subtype and & lt;i& gt;YEATS4& lt;/ i& gt;'s oncogenic role. Journal: Frontiers in immunologyIn common: genetics / omics, other condition, 7 references - [2] doi:10.3389/fimmu.2025.1567970
- The role of ATF3 in precision medicine of brain arteriovenous malformation: based on endothelial cell proliferation.Journal: Frontiers in immunologyIn common: genetics / omics, 6 references
- [3] doi:10.3389/fimmu.2024.1434300
- IGFBP7+ subpopulation and IGFBP7 risk score in astrocytoma: insights from scRNA-Seq and bulk RNA-Seq.Journal: Frontiers in immunologyIn common: NCBI GEO GSE182109, genetics / omics, other condition, 3 references
- [4] doi:10.1186/s12974-025-03551-y
- IL-1β&
lt;sup& gt;+& lt;/ sup& gt; tumor-associated macrophages accelerate glioblastoma progression by amplifying the PGE2-EP4 signaling. Journal: Journal of neuroinflammationIn common: NCBI GEO GSE182109, genetics / omics, other condition, 1 reference - [5] doi:10.1007/s12672-024-01685-8
- Exploring the role of Disulfidptosis in glioma progression: insights into tumor heterogeneity and therapeutic potential through single-cell RNA sequencing.Journal: Discover oncologyIn common: NCBI GEO GSE182109, genetics / omics, other condition, 1 reference
- [6] doi:10.1186/s13578-024-01218-4 [code]
- Revealing the role of SPP1<sup>+</
sup> macrophages in glioma prognosis and therapeutic targeting by investigating tumor-associated macrophage landscape in grade 2 and 3 gliomas. Journal: Cell & bioscienceIn common: NCBI GEO GSE182109, genetics / omics, other condition, 1 reference - [7] doi:10.3390/cells14191540
- Integrated Spatial and Single-Cell Transcriptomics Reveals Poor Prognostic Ligand-Receptor Pairs in Glioblastoma.Journal: CellsIn common: NCBI GEO GSE182109, genetics / omics, other condition, 1 reference
- [8] doi:10.1155/2022/7843863
- TUG1/
MAZ/ FTH1 Axis Attenuates the Antiglioma Effect of Dihydroartemisinin by Inhibiting Ferroptosis. Journal: Oxidative medicine and cellular longevityIn common: other condition, 3 references - [9] doi:10.1155/prm/2444554
- Dissection of Microglial Heterogeneity and Identification of Pain-Related Subpopulations After Traumatic Brain Injury.Journal: Pain research & managementIn common: genetics / omics, 3 references
- [10] doi:10.1016/j.isci.2026.115982 [code]
- Multi-omics profiling-derived signature links cellular ecosystem to glioblastoma prognosis.Journal: iScienceIn common: NCBI GEO GSE182109, genetics / omics, other condition
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
